DNA Synthesis Market By Product Type (Oligonucleotide Synthesis, Gene Synthesis, Custom Libraries, Consumables & Reagents); By Application (Therapeutics Development, Diagnostics, Synthetic Biology, Academic Research); By End User (Biotechnology Companies, Pharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global DNA Synthesis Market is projected to expand at a robust CAGR of 14.43%, rising from $2.78 billion in 2024 to $13.6 billion by 2030, supported by gene synthesis, oligonucleotide synthesis, synthetic biology, genomics, PCR primers, and biotechnology, as per Strategic Market Research.

 

DNA synthesis refers to the artificial creation of deoxyribonucleic acid (DNA) sequences, enabling the design and construction of genes, genetic circuits, and entire genomes for a wide range of scientific, industrial, and therapeutic applications. From synthetic biology start-ups designing custom organisms to pharmaceutical giants accelerating vaccine development, DNA synthesis has become a cornerstone of modern biotechnology.

 

The market’s strategic relevance between 2024 and 2030 is driven by four critical macro forces:

• Accelerating Biomedical Research: Academic and private institutions are scaling up genomic projects, driving demand for faster and more accurate DNA synthesis platforms.

• Therapeutics Pipeline Expansion: Personalized medicine and cell and gene therapies rely on precision-designed genetic material, expanding industrial uptake.

• Automation and Microfluidics Integration: The convergence of microfluidics, robotics, and AI has dramatically improved synthesis throughput and error correction, supporting economies of scale.

• Global Biosecurity Concerns: Governments and NGOs are investing in secure synthesis infrastructure to prevent misuse of synthetic sequences.
   

Key stakeholders shaping the market include:

• Original Equipment Manufacturers (OEMs): Providers of benchtop and industrial DNA synthesizers.

• Biotech and Pharmaceutical Companies: End-users creating therapies and diagnostics.

• Contract Research Organizations (CROs): Partners for outsourced synthesis services.

• Government Agencies and Regulatory Bodies: Influencers of safety standards and funding flows.

• Investors and Venture Capital Firms: Catalysts funding innovation pipelines.

Over the forecast period, adoption will deepen as DNA synthesis becomes integral to drug discovery, agricultural innovation, and synthetic biology ventures. The sector is also expected to benefit from geopolitical investments in life sciences infrastructure and biofoundry capacity.

 

Comprehensive Market Snapshot

• The Global DNA Synthesis Market is projected to expand at a robust 14.43% CAGR, rising from USD 2.78 billion in 2024 to USD 13.6 billion by 2030, driven by accelerating adoption across genomics research, molecular diagnostics, synthetic biology, and gene-based therapeutics.

• Based on a 36.83% share of the 2024 global market, the USA DNA Synthesis Market is estimated at USD 1.02 billion in 2024, and at a 13.35% CAGR is projected to reach USD 2.15 billion by 2030.

• With a 22.0% share, the Europe DNA Synthesis Market is estimated at USD 0.61 billion in 2024, and at a 12.24% CAGR is expected to reach USD 1.23 billion by 2030.

• With a 14.0% share, the Asia Pacific (APAC) DNA Synthesis Market is estimated at USD 0.39 billion in 2024, and at a 21.0% CAGR is projected to reach USD 1.24 billion by 2030, reflecting aggressive capacity expansion and synthetic biology investments.

Regional Insights

• North America (USA) accounted for the largest market share of 36.83% in 2024, supported by strong funding in genomics, advanced biotech infrastructure, and early adoption of high-throughput synthesis platforms.

• Asia Pacific (APAC) is expected to expand at the fastest CAGR of 21.0% during 2024–2030, driven by rapidly scaling biotech hubs, government-backed synthetic biology programs, and cost-competitive manufacturing.

 

By Product Type

• Oligonucleotide Synthesis held the largest market share of 41.0% in 2024, reflecting its indispensable role in PCR primers, probes, sequencing adapters, and molecular diagnostics.

• Gene Synthesis is projected to grow at a notable CAGR over 2024–2030, driven by increasing demand for full-length genes and multi-gene constructs in cell and gene therapy pipelines.

Estimated 2024 Market Split (Global)

• Oligonucleotide Synthesis accounted for the largest market share of 41.0% in 2024, reflecting its indispensable role in PCR primers, probes, sequencing adapters, and molecular diagnostics, with an estimated market value of approximately USD 1.14 billion.

• Gene Synthesis represented 27.0% of the global market in 2024, valued at approximately USD 0.75 billion, and is projected to grow at a notable CAGR over 2024–2030 due to increasing demand for full-length genes and multi-gene constructs in cell and gene therapy pipelines.

• Custom Libraries captured 18.0% of the market in 2024, corresponding to an estimated value of approximately USD 0.50 billion, supported by rising adoption in high-throughput screening and synthetic biology workflows.

• Consumables & Reagents accounted for the remaining 14.0% share in 2024, with a market value of approximately USD 0.39 billion, driven by recurring demand for synthesis inputs and workflow reagents.

 

By Application

• Diagnostics accounted for the highest market share of 32.0% in 2024, supported by widespread use of synthetic primers and probes in infectious disease and genetic testing.

• Therapeutics Development is anticipated to be the fastest-growing application segment during 2024–2030, supported by rising FDA approvals of gene- and cell-based therapies requiring precision DNA constructs.

Estimated 2024 Market Split (Global)

• Diagnostics held the highest market share of 32.0% in 2024, supported by widespread use of synthetic primers and probes in infectious disease and genetic testing, translating to approximately USD 0.89 billion in revenue.

• Therapeutics Development accounted for 29.0% of the global market in 2024, valued at approximately USD 0.81 billion, and is anticipated to be the fastest-growing application segment through 2030, driven by rising FDA approvals of gene- and cell-based therapies requiring precision DNA constructs.

• Synthetic Biology represented 21.0% of the market in 2024, with an estimated value of approximately USD 0.58 billion, reflecting expanding use in pathway engineering and organism design.

• Academic Research contributed 18.0% of total market revenue in 2024, equivalent to approximately USD 0.50 billion, supported by ongoing basic and translational research activities.

 

By End User

• Biotechnology Companies contributed the largest share of 38.0% in 2024, reflecting their central role in synthetic biology, gene editing, and therapeutic innovation.

• Contract Research Organizations (CROs) are anticipated to expand at a robust CAGR over 2024–2030, driven by increasing outsourcing of DNA synthesis, validation, and library construction.

Estimated 2024 Market Split (Global)

• Biotechnology Companies contributed the largest share of 38.0% in 2024, reflecting their central role in synthetic biology, gene editing, and therapeutic innovation, with a corresponding market value of approximately USD 1.06 billion.

• Pharmaceutical Companies accounted for 26.0% of the global market in 2024, valued at approximately USD 0.72 billion, driven by growing integration of synthetic DNA in drug discovery and development pipelines.

• Academic & Research Institutions represented 22.0% of the market in 2024, translating to an estimated value of approximately USD 0.61 billion, supported by publicly funded research programs and collaborative projects.

• Contract Research Organizations (CROs) held 14.0% of the market in 2024, valued at approximately USD 0.39 billion, and are expected to expand at a robust CAGR over 2024–2030 due to increased outsourcing of DNA synthesis and validation services.

 

By Treatment Setting

• Hospitals captured the largest market share of 40.0% in 2024, reflecting strong demand for diagnostic-grade oligonucleotides and clinical research support.

• Telehealth Platforms are expected to witness accelerated growth throughout 2024–2030, supported by decentralized diagnostics and remote genetic testing workflows.

Estimated 2024 Market Split (Global)

• Hospitals captured the largest market share of 40.0% in 2024, reflecting strong demand for diagnostic-grade oligonucleotides and clinical research support, with an estimated market value of approximately USD 1.11 billion.

• Ambulatory Surgical Centers accounted for 25.0% of the global market in 2024, valued at approximately USD 0.70 billion, driven by growing procedural diagnostics and clinical testing volumes.

• Diagnostic Imaging Centers represented 20.0% of the market in 2024, with an estimated value of approximately USD 0.56 billion, supported by integration of molecular diagnostics alongside imaging workflows.

• Telehealth Platforms held 15.0% of the market in 2024, valued at approximately USD 0.42 billion, and are expected to witness accelerated growth through 2024–2030 due to decentralized diagnostics and remote genetic testing models.

 

Strategic Questions Guiding the Evolution of the Global DNA Synthesis Market

1. What products, synthesis formats, and service offerings are explicitly included within the DNA Synthesis market, and which adjacent capabilities (e.g., sequencing, editing, storage) are considered out of scope?

2. How does the DNA Synthesis Market differ structurally from adjacent markets such as genomics tools, gene editing, synthetic biology platforms, and molecular diagnostics?

3. What is the current and forecasted size of the Global DNA Synthesis Market, and how is value distributed across key product and service segments?

4. How is revenue allocated between oligonucleotide synthesis, gene synthesis, custom libraries, and consumables, and how is this mix expected to evolve over time?

5. Which application segments (e.g., diagnostics, therapeutics development, synthetic biology, academic research) account for the largest and fastest-growing revenue pools?

6. Which segments contribute disproportionately to profit and margin generation, rather than synthesis volume alone?

7. How does demand differ between short-sequence, long-sequence, and high-complexity DNA constructs, and how does this influence pricing and supplier selection?

8. How are standard, premium, and high-fidelity synthesis tiers evolving within customer procurement and usage pathways?

9. What role do turnaround time, error rates, re-synthesis frequency, and long-term customer retention play in segment-level revenue growth?

10. How are research funding levels, clinical trial activity, and synthetic biology adoption shaping demand across DNA Synthesis segments?

11. What technical, regulatory, or quality-related constraints limit adoption in specific synthesis lengths, applications, or geographies?

12. How do pricing pressure, cost-per-base trends, and customer budget constraints influence revenue realization across different synthesis segments?

13. How strong is the current and mid-term innovation pipeline, and which emerging synthesis technologies or chemistries could redefine competitive advantage?

14. To what extent will next-generation synthesis platforms expand the addressable customer base versus intensify competition within existing segments?

15. How are automation, miniaturization, and AI-driven design tools improving accuracy, scalability, and customer workflow integration?

16. How will commoditization and technology standardization reshape competition across core DNA synthesis segments?

17. What role will low-cost providers, regional manufacturing hubs, and in-house synthesis capabilities play in pricing erosion and access expansion?

18. How are leading suppliers aligning product portfolios, capacity investments, and service models to defend or grow market share?

19. Which geographic markets are expected to outperform global growth in the DNA Synthesis Market, and which applications are driving this outperformance?

20. How should manufacturers, service providers, and investors prioritize specific segments and regions to maximize long-term value creation in the DNA Synthesis Market?

 

Segment-Level Insights and Market Structure — DNA Synthesis Market

The DNA Synthesis Market is organized around distinct product categories, application domains, end-user groups, and delivery models that reflect differences in sequence complexity, turnaround expectations, quality requirements, and integration into downstream workflows. Each segment contributes uniquely to overall market value, competitive positioning, and long-term growth potential, shaped by advances in genomics, biotechnology innovation cycles, and evolving research and clinical use cases.

Product Type Insights:

Oligonucleotide Synthesis

Oligonucleotide synthesis represents the most established and commercially pervasive segment within the DNA synthesis market. Short DNA sequences are essential components of molecular biology workflows, supporting applications such as PCR amplification, sequencing preparation, probe design, and diagnostic assay development. The segment benefits from high repeat usage, standardized synthesis processes, and broad adoption across research, diagnostics, and clinical laboratories. From a market perspective, oligonucleotide synthesis delivers consistent volume demand and recurring revenue streams, anchoring the overall market while continuing to evolve through improvements in fidelity, speed, and customization.

Gene Synthesis

Gene synthesis addresses the growing need for longer, functionally complete DNA constructs, including full-length genes and multi-gene assemblies. This segment is closely tied to innovation-driven fields such as gene therapy, cell engineering, and advanced synthetic biology. Compared to oligonucleotides, gene synthesis involves greater technical complexity, higher value per order, and more stringent quality control. As biological systems become more engineered and modular, gene synthesis is gaining strategic importance, positioning it as a key growth engine within the broader DNA synthesis ecosystem.

Custom DNA Libraries

Custom DNA libraries enable large-scale exploration of genetic variation by providing pools of designed sequences for screening and discovery. These libraries are widely used in applications such as protein engineering, functional genomics, and pathway optimization. Market demand for custom libraries is driven by the shift toward high-throughput experimentation and data-driven biological design. Although more specialized than other product categories, this segment commands strong strategic value due to its role in accelerating discovery timelines and enabling large-scale biological experimentation.

Consumables and Reagents

Consumables and reagents form the enabling backbone of DNA synthesis workflows, supplying enzymes, nucleotides, buffers, and synthesis kits required for in-house and outsourced operations. While individual product pricing is lower than synthesized sequences, this segment benefits from steady demand and repeat purchasing behavior. Its importance increases as more organizations invest in partial internalization of synthesis capabilities, reinforcing its role as a stabilizing and supportive component of the overall market.

 

Application Insights:

Diagnostics

DNA synthesis is a foundational input for molecular diagnostics, supporting the development of primers, probes, and assay components used in infectious disease testing, genetic screening, and oncology diagnostics. This application segment emphasizes reliability, reproducibility, and regulatory-grade quality. Market demand is shaped by expanding diagnostic testing volumes and the continued shift toward nucleic-acid-based detection technologies.

Therapeutics Development

Therapeutics development represents one of the most dynamic application areas for DNA synthesis. Gene and cell therapy programs rely heavily on precise, high-fidelity DNA constructs for vector design, construct optimization, and preclinical validation. As advanced therapies progress through clinical pipelines, this segment increasingly drives demand for longer sequences, higher purity standards, and rapid iteration, making it a central growth catalyst within the market.

Synthetic Biology

In synthetic biology, DNA synthesis enables the rational design and engineering of biological systems for industrial, agricultural, and environmental applications. This segment emphasizes scalability, design flexibility, and integration with computational tools. Demand growth is linked to the expanding use of engineered organisms for chemical production, biofuels, and novel biomaterials, positioning synthetic biology as a structurally important application segment.

Academic and Fundamental Research

Academic and research institutions continue to represent a significant and stable source of DNA synthesis demand. This segment supports foundational work in genomics, molecular biology, and systems biology. While price sensitivity is higher compared to commercial users, academic demand contributes to volume stability and long-term innovation by sustaining early-stage discovery and training future industry users.

 

End-User Insights:

Biotechnology Companies

Biotechnology companies are the primary commercial drivers of DNA synthesis demand, leveraging synthesized DNA across product development, platform optimization, and scale-up activities. Their purchasing behavior emphasizes speed, accuracy, and customization, often favoring premium synthesis services. This segment contributes disproportionately to market value relative to volume, reflecting its innovation-centric use cases.

Pharmaceutical Companies

Pharmaceutical companies increasingly integrate DNA synthesis into drug discovery, biologics development, and advanced therapeutic research. While historically less synthesis-intensive than biotech firms, pharma demand is rising as genetic and cell-based modalities become more central to pipeline strategies. This segment values compliance, reproducibility, and long-term supplier relationships.

Academic and Research Institutions

Universities and public research organizations remain core end users, supporting exploratory research and method development. Their demand profile is characterized by diverse project needs, smaller order sizes, and a preference for cost-effective solutions, contributing to baseline market demand and long-term ecosystem development.

Contract Research Organizations (CROs)

CROs serve as intermediaries that aggregate DNA synthesis demand on behalf of multiple clients. Their role is expanding as outsourcing increases across research and development workflows. CRO demand is closely tied to project-based activity and emphasizes reliability, turnaround time, and scalability, reinforcing their growing influence within the market structure.

 

Segment Evolution Perspective

While oligonucleotide synthesis continues to anchor current revenue generation, higher-complexity segments such as gene synthesis and custom libraries are increasingly shaping future growth trajectories. At the same time, application demand is shifting toward therapeutics development and synthetic biology, reflecting broader transformation in life-science innovation. Collectively, these segment-level dynamics are redefining how value, differentiation, and competitive advantage are distributed across the DNA synthesis market over the forecast period.

 

Table: Key Commercial Platforms and Late-Stage Technologies in the DNA Synthesis Market

Product / Platform	Company / Development Status	Target / Core Technology / Mechanism
GeneArt™ Custom Gene Synthesis	Thermo Fisher Scientific — Commercial	Custom gene synthesis with sequence optimization and verification workflows
Ultramer™ DNA Oligos	Integrated DNA Technologies (IDT) — Commercial	Long, high-quality oligonucleotide synthesis for demanding molecular biology and gene construction use cases
gBlocks® Gene Fragments	Integrated DNA Technologies (IDT) — Commercial	Double-stranded synthetic DNA fragments manufactured using high-fidelity synthesis chemistries (gene fragment “write” products)
Twist Oligo Pools	Twist Bioscience — Commercial	High-throughput, silicon-based DNA synthesis platform producing large, complex ssDNA oligo pools
SurePrint Oligo Pools	Agilent Technologies — Commercial	Pooled oligo synthesis using high-throughput parallel DNA writing (custom oligo pools for screens and libraries)
BioXp® System (DNA printer / benchtop synthesis & assembly)	Telesis Bio (formerly Codex DNA) — Commercial	Automated, hands-free benchtop workflow enabling rapid synthesis/assembly of biological sequences
SYNTAX™ System (enzymatic DNA synthesis platform)	DNA Script — Late-stage commercialization	Enzymatic DNA synthesis leveraging engineered TdT and reversibly terminated nucleotides
FLASH Gene (Gene Synthesis)	GenScript — Commercial	Rapid-turnaround gene synthesis service, positioned for accelerated build cycles
Custom Oligonucleotide Synthesis	Eurofins Genomics — Commercial	Chemical oligo synthesis (phosphoramidite chemistry) with QC-driven production for research and applied workflows
Thermally Controlled Semiconductor DNA Synthesis Platform	Evonetix — Late-stage development / early access deployments	Semiconductor chip + thermally controlled synthesis chemistry aimed at higher-fidelity gene-length DNA creation
DNA-based Data Storage / Compute Using Synthetic DNA	Catalog Technologies — Late-stage development / early commercial demonstrations	Uses synthetic DNA as an information medium; approach emphasizes scalable encoding/replication rather than routine research oligo supply

 

Key Recent Developments by Companies in the DNA Synthesis Market

Twist Bioscience:

• Long gene fragments extend construct length into multi-element designs (USA)
  Twist expanded its gene offering with long gene fragments reaching 50 kb, enabling researchers to consolidate more regulatory elements, homology regions, and multi-part designs into fewer build steps—reducing iterative assembly cycles in synthetic biology and vector engineering workflows.

• Rapid gene synthesis scaled across prep formats for faster build cycles (USA)
  Twist expanded its Express Genes rapid synthesis service to support additional plasmid preparation scales (including larger preps), aligning the product with high-throughput discovery needs where “design → build → test” loops must run in tight timelines.

Integrated DNA Technologies (IDT):

• “Rapid Genes” launch + gene synthesis upgrades for faster screening (USA)
  IDT launched Rapid Genes—NGS-verified clonal genes shipped in as little as five business days—and paired the release with upgrades to its gene synthesis offering, targeting pharmaceutical and synthetic biology users seeking faster, automation-friendly DNA inputs for screening and construct evaluation.

Thermo Fisher Scientific:

• GeneArt ordering workflow consolidated into a modern design-and-order dashboard (Global)
  Thermo Fisher transitioned GeneArt customers from the legacy portal to the GeneArt Services Dashboard (powered by the Instant Designer experience), centralizing construct design, quoting, and order management—an operational modernization that reduces friction for repeat DNA ordering and complex construct configuration.

GenScript:

• FLASH Gene service positioned for faster, cost-competitive gene synthesis throughput (USA)
  GenScript launched FLASH Gene, emphasizing rapid turnaround and affordability, and linked the offering to manufacturing expansion (notably its New Jersey footprint), reinforcing the competitive axis of speed + scale in commercial gene synthesis.

DNA Script:

• Benchtop enzymatic DNA synthesis pushes “in-house” DNA writing for rapid iteration (France/USA footprint)
  DNA Script continued commercial focus on its SYNTAX / STX-200 benchtop enzymatic DNA synthesis approach (up to ~120 nt oligos with its kits), positioning on-demand in-lab synthesis as a productivity lever for teams that want tighter control over timelines and design iteration.

Eurofins Genomics:

• New high-throughput oligo production platform targets lower-cost access (USA/Europe)
  Eurofins highlighted development of a new production platform aimed at producing oligos at a more attractive price point, signaling ongoing industrial optimization (automation + throughput) to broaden access to synthesis beyond premium-only use cases.

Agilent Technologies:

• High-complexity pooled DNA synthesis keeps advancing for screening-heavy workflows (USA)
  Agilent’s SurePrint platform messaging and materials increasingly emphasize high-fidelity pooled oligo synthesis for protein engineering, directed evolution, pooled screens, and large library builds—reinforcing the shift toward massively parallel DNA “writing” as a core enabler of high-throughput biology.

Telesis Bio:

• BioXp workflow expansions strengthen automated “build” steps around DNA assembly (USA)
  Telesis Bio continued expanding BioXp-supported workflows with kits that enable automated cloning/assembly use cases (e.g., building clones from fragments and vectors), keeping benchtop automation relevant for labs seeking standardized, lower-hands-on DNA build pipelines.

 

Market Segmentation And Forecast Scope

The DNA synthesis market can be segmented comprehensively to reflect the diverse ways genetic material is created, delivered, and applied. For this report, the segmentation is structured along four primary axes: By Product Type , By Application , By End User , and By Region .

By Product Type

• Oligonucleotide Synthesis: Short DNA fragments critical for PCR primers, probes, and sequencing adapters. This segment accounted for an estimated 41% of market revenue in 2024 .

• Gene Synthesis: Longer DNA constructs including entire genes or genetic circuits.

• Custom Libraries: Large-scale pools of synthetic sequences for screening.

• Consumables & Reagents: Enzymes, nucleotides, and kits that enable synthesis workflows.

Oligonucleotide Synthesis is projected to remain the most commercially dominant category, owing to its widespread use across diagnostics, research, and therapeutics.

 

By Application

• Therapeutics Development: Gene and cell therapy pipelines depend on accurate DNA synthesis for construct design.

• Diagnostics: Custom probes and primers enable molecular diagnostics and infectious disease testing.

• Synthetic Biology: Engineering of organisms for industrial production of enzymes, chemicals, and biofuels.

• Academic Research: Fundamental studies in genomics and systems biology.

Therapeutics Development is anticipated to be the fastest-growing application segment, supported by increasing FDA approvals for gene-based treatments.

 

By End User

• Biotechnology Companies: Innovators commercializing synthetic biology and therapeutic platforms.

• Pharmaceutical Companies: Users integrating synthesis into drug discovery and manufacturing.

• Academic & Research Institutions: Core facilities and labs requiring high-fidelity sequences.

• Contract Research Organizations (CROs): Outsourced providers of synthesis and validation services.

 

By Region

• North America: The largest market, driven by advanced genomics infrastructure.

• Europe: Strong growth due to supportive regulatory frameworks and R&D funding.

• Asia Pacific: Fastest-growing region, with China and India expanding biotechnology capabilities.

• Latin America, Middle East & Africa: Emerging regions with increasing adoption among research institutes.

 

Forecast Scope (2024–2030):

• Market size estimates, growth rates, and revenue projections are presented by each segment.

• The report reveals that Asia Pacific is projected to expand at an inferred CAGR of 21% , outpacing other regions due to scaling investments in biofoundries and government support for synthetic biology.

These segmentation insights help stakeholders align product development, marketing, and regional expansion strategies with the most promising growth areas.

 

Market Trends And Innovation Landscape

The DNA synthesis market is evolving rapidly as scientific ambition meets technological ingenuity. From benchtop synthesizers to cloud-based design tools, innovation is unlocking new frontiers in genetic engineering.

1. Automation and Miniaturization

Leading companies are integrating microfluidics and robotics into synthesis platforms, reducing reagent consumption while increasing throughput. Benchtop synthesizers are now capable of producing thousands of oligos per day, supporting distributed research and small-batch manufacturing.

 

2. Error Correction and High-Fidelity Synthesis

Error rates have historically limited the utility of longer sequences. Innovations in enzymatic synthesis, advanced error-correction chemistries, and machine learning algorithms are now enabling high-fidelity gene assembly. This progress is especially important for therapeutic applications, where even a single nucleotide error can compromise safety.

 

3. Cloud-Based Design Platforms

Software solutions for sequence design and ordering are becoming more sophisticated, integrating:

• AI-powered optimization of codon usage.

• Predictive modeling of secondary structures.

• Regulatory compliance screening. These tools allow researchers to seamlessly transition from in silico design to real-world synthesis.

 

4. Enzymatic DNA Synthesis

While chemical phosphoramidite methods have long dominated the industry, enzymatic synthesis technologies are gaining traction. Enzymatic approaches promise faster production cycles, longer constructs, and reduced environmental impact. Several startups have attracted substantial venture funding to commercialize these techniques.

 

5. Strategic Collaborations and M&A Activity

The market is marked by a flurry of partnerships and acquisitions. In the past 24 months:

• Instrument manufacturers have partnered with bioinformatics firms to integrate end-to-end workflows.

• Synthetic biology companies have merged to consolidate expertise and IP.

• Large pharmaceutical companies have signed agreements with synthesis providers to secure supply chains for gene therapy pipelines.

Industry observers anticipate that M&A activity will accelerate, as players compete to offer turnkey solutions combining hardware, consumables, and digital design.

 

6. Regulatory Emphasis on Biosecurity

Governments are strengthening oversight frameworks to ensure that DNA synthesis tools are not misused for illicit purposes. Providers are investing in sequence screening technologies to flag pathogenic sequences, a trend expected to shape procurement policies.

According to domain experts, “Over the next five years, DNA synthesis will become more commoditized, but differentiation will emerge from platform integration, automation, and regulatory compliance readiness.”

 

Competitive Intelligence And Benchmarking

The DNA synthesis market features a diverse landscape of established leaders, high-growth innovators, and niche specialists. Competition centers on technological differentiation, pricing, scalability, and service integration. Below are six prominent companies shaping the market trajectory:

1. Twist Bioscience Twist Bioscience is recognized for its silicon-based DNA synthesis platform, which dramatically increases throughput while reducing cost per base. The company emphasizes rapid turnaround, custom library construction, and partnerships with drug developers. Its expansion into enzymatic DNA synthesis reflects a strategy of hedging technological bets while scaling industrial capacity.

 

2. Thermo Fisher Scientific As a diversified life sciences conglomerate, Thermo Fisher integrates oligonucleotide synthesis into a broad portfolio of genomic and laboratory solutions. The company leverages global distribution networks and robust logistics infrastructure to serve pharmaceutical, academic, and diagnostics clients. Thermo Fisher’s focus on regulatory-compliant manufacturing is a critical differentiator for therapeutic applications.

 

3. Integrated DNA Technologies (IDT) A leading provider of synthetic oligonucleotides, IDT offers high-fidelity DNA synthesis, RNA synthesis, and CRISPR components. The company’s strengths include custom design software and a reputation for stringent quality control. Recent investments have enhanced automation and expanded production in Europe and Asia Pacific.

 

4. GenScript GenScript has grown into one of the largest gene synthesis providers globally. It combines synthetic biology services with custom peptide synthesis, cell line development, and CRISPR solutions. The company emphasizes affordable gene constructs and scalable manufacturing, catering to academic and industrial clients alike.

 

5. DNA Script DNA Script is pioneering enzymatic DNA synthesis, positioning itself as a disruptor to conventional chemical methods. The company’s benchtop instrument platform enables decentralized production of synthetic DNA, appealing to labs seeking control over sequence creation. Strategic funding rounds have underpinned commercialization efforts and international expansion.

 

6. Eurofins Genomics Eurofins offers an extensive catalog of oligonucleotides and gene synthesis services. Its strategy focuses on rapid delivery in Europe and North America, competitive pricing tiers, and integration with broader genomics testing capabilities. Eurofins has also invested in bioinformatics platforms to streamline design and ordering.

 

Competitive Dynamics and Positioning

• Scale and Automation: Twist Bioscience and GenScript have invested heavily in high-capacity manufacturing, enabling lower prices and faster delivery.

• Technology Differentiation: DNA Script’s enzymatic synthesis model is a unique proposition gaining market interest.

• Global Reach: Thermo Fisher and Eurofins leverage expansive distribution to serve multinational customers.

• Regulatory Expertise: IDT and Thermo Fisher maintain robust compliance infrastructures critical for therapeutic applications.

Analysts forecast intensified competition as start-ups push the boundaries of speed, accuracy, and environmental sustainability, while established firms focus on strategic acquisitions.

 

Regional Landscape And Adoption Outlook

Regional dynamics in the DNA synthesis market reveal distinct growth patterns, shaped by infrastructure maturity, regulatory environments, and R&D investments. Below is an in-depth look at adoption trends across North America, Europe, Asia Pacific, and LAMEA (Latin America, Middle East & Africa).

North America

North America remains the largest market , with the United States accounting for the majority of demand. Key growth drivers include:

• A dense cluster of biotechnology and pharmaceutical companies.

• Robust federal funding through the National Institutes of Health (NIH) and the Department of Defense .

• Early adoption of benchtop DNA synthesizers in academic and contract research labs.

Canada is also emerging as a significant contributor, with government grants supporting biofoundry infrastructure and synthetic biology innovation.

 

Europe

Europe’s market is propelled by:

• Strong regulatory frameworks that encourage safe synthetic biology practices.

• Initiatives such as the European Union’s Horizon Europe program, which funds genomic research.

• Rising adoption among contract research organizations in Germany, the UK, and France.

Germany is the region’s clear leader, benefiting from high public and private R&D expenditures.

 

Asia Pacific

Asia Pacific is the fastest-growing region , with an inferred CAGR of 21% between 2024 and 2030. Key drivers include:

• China’s massive investments in genomic sequencing and synthetic biology platforms.

• India’s growing cluster of biotech startups and research parks.

• Japan’s focus on integrating DNA synthesis into regenerative medicine and advanced therapeutics.

China, in particular, has launched multiple state-backed projects to develop indigenous capabilities in high-fidelity DNA synthesis and reduce dependency on Western suppliers.

 

Latin America, Middle East & Africa (LAMEA)

While smaller in overall market share, LAMEA is seeing steady growth as awareness and infrastructure improve:

• Brazil leads Latin America with expanding biotech hubs in São Paulo.

• The UAE and Saudi Arabia are making strategic investments to build life sciences capacity.

• South Africa is emerging as a research center for agricultural genomics and infectious disease diagnostics.

White space opportunities remain substantial, especially in underserved African and Middle Eastern nations where supply chains for reagents and equipment are still developing.

 

Regional Comparison Snapshot

Region	Market Position	Notable Trends
North America	Largest market	Mature regulatory frameworks, strong pharma presence
Europe	Established, growing steadily	Public funding, CRO expansion
Asia Pacific	Fastest-growing	Government-backed synthetic biology programs
LAMEA	Emerging	Infrastructure investments, regional capacity building

Experts note that regional strategies will increasingly hinge on regulatory compliance, local partnerships, and investment in training skilled personnel.

 

End-User Dynamics And Use Case

The DNA synthesis market caters to a diverse range of end users, each driving demand with unique workflows and objectives. Understanding these dynamics is essential for stakeholders aiming to tailor their products and services effectively.

Biotechnology Companies

These firms are often the most innovative customers, leveraging synthetic DNA to engineer microbes, create novel biologics, and develop bio-based manufacturing processes. Many biotech start-ups prioritize flexible supply chains and integration with cloud-based design tools to accelerate product development.

 

Pharmaceutical Companies

Pharma companies increasingly rely on DNA synthesis to fuel drug discovery pipelines and support cell and gene therapy development. High-fidelity, GMP-compliant sequences are critical for regulatory submissions and clinical production. Large pharmaceutical companies often engage in long-term agreements with synthesis providers to secure consistent quality and volume.

 

Academic and Research Institutions

Universities and research centers use synthetic DNA in basic research, including genome editing, epigenetics, and synthetic biology exploration. Demand here is driven by:

• Competitive grant funding.

• Collaboration networks that span continents.

• The need for customized, short-run sequences.

Academic users frequently value technical support and flexible order quantities over scale alone.

 

Contract Research Organizations (CROs)

CROs serve as intermediaries, executing outsourced synthesis, validation, and delivery. These organizations have emerged as critical partners for small and mid-sized biotech companies lacking in-house capabilities.

 

Use Case Scenario

A tertiary hospital research institute in South Korea sought to accelerate the development of a gene therapy candidate targeting a rare metabolic disorder. The team required a series of high-fidelity gene constructs with minimal error rates to support preclinical studies. Partnering with a DNA synthesis company offering enzymatic synthesis and robust error correction, the institute reduced design-to-delivery timelines by 35%. The project demonstrated how integrated design software and on-demand synthesis capabilities can enable faster validation cycles and higher confidence in construct integrity.

This scenario underscores the procedural value of next-generation synthesis technologies: improving speed-to-data, reducing costs associated with iteration, and enhancing patient outcomes in precision medicine.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Twist Bioscience launched a scalable silicon-based platform upgrade, enhancing throughput by nearly 50% and reducing error rates in long gene constructs.

• DNA Script received CE-IVD marking for its benchtop enzymatic DNA synthesis system, paving the way for decentralized synthesis in European clinical labs.

• GenScript expanded its Singapore manufacturing hub to increase production capacity for custom gene constructs and oligonucleotides, supporting growing Asia Pacific demand.

• Thermo Fisher Scientific signed multiple agreements with pharma companies to supply GMP-grade synthetic DNA for cell and gene therapy programs.
   

Opportunities

• Rise of Personalized Medicine: Increasing approvals of gene therapies and precision treatments are driving demand for custom, high-fidelity DNA constructs.

• Enzymatic Synthesis Adoption: Enzymatic platforms are opening new revenue streams with faster turnaround, longer sequences, and lower environmental impact.

• Emerging Market Expansion: Rapid infrastructure development in Asia Pacific and Latin America presents large untapped customer bases.

 

Restraints

• Regulatory Complexity: Strict biosecurity and compliance frameworks can delay product launches and restrict cross-border synthesis.

• High Capital Costs: Setting up advanced synthesis facilities requires substantial upfront investment, limiting new entrants.

Taken together, these dynamics suggest a market poised for strong expansion but demanding careful navigation of compliance and operational complexity.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 2.78 Billion
Revenue Forecast in 2030	USD 13.6 Billion
Overall Growth Rate	CAGR of 14.43% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Oligonucleotide Synthesis, Gene Synthesis, Custom Libraries, Consumables & Reagents
By Application	Therapeutics Development, Diagnostics, Synthetic Biology, Academic Research
By End User	Biotechnology Companies, Pharmaceutical Companies, Academic & Research Institutions, CROs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Personalized Medicine Growth - Enzymatic Synthesis Adoption - Emerging Market Expansion
Customization Option	Available upon request